Human CA125/MUC16 Antibody
R&D Systems, part of Bio-Techne | Catalog # MAB56091
Key Product Details
Species Reactivity
Applications
Label
Antibody Source
Product Specifications
Immunogen
Met13360-Gln14347 (Met13472Thr & Gln13957Lys)
Accession # NP_078966.2
Specificity
Clonality
Host
Isotype
Scientific Data Images for Human CA125/MUC16 Antibody
Detection of CA125/MUC16 in HeLa Human Cell Line by Flow Cytometry.
HeLa human cervical cancer cell line was stained with Mouse Anti-Human CA125/MUC16 Monoclonal Antibody (Catalog # MAB56091, filled histogram) or isotype control antibody (MAB002, open histogram), followed by Allophycocyanin-conjugated Anti-Mouse IgG Secondary Antibody (F0101B). View our protocol for Staining Membrane-associated Proteins.CA125/MUC16 in Human Ovarian Cancer Tissue.
Ovarian Cancer Antigen CA125 (CA125/MUC16) was detected in immersion fixed paraffin-embedded sections of human ovarian cancer tissue using Mouse Anti-Human CA125/MUC16 Monoclonal Antibody (MAB56091) at 5 µg/mL for 1 hour at room temperature followed by incubation with the Anti-Mouse IgG VisUCyte™ HRP Polymer Antibody (VC001). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to cell surfaces. View our protocol for IHC Staining with VisUCyte HRP Polymer Detection Reagents.Detection of CA125/MUC16 in OVCAR-3 cells by Flow Cytometry
OVCAR-3 cells were stained with Mouse Anti-Human CA125/MUC16 Monoclonal Antibody (Catalog # MAB56091, filled histogram) or isotype control antibody (Catalog # MAB002, open histogram) followed by Fluorescein-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # F0103B). View our protocol for Staining Membrane-associated Proteins.Applications for Human CA125/MUC16 Antibody
CyTOF-ready
Flow Cytometry
Sample: HeLa human cervical cancer cell line; OVCAR-3 human ovarian carcinoma cell line
Immunohistochemistry
Sample: Immersion fixed paraffin-embedded sections of human ovarian cancer tissue
Formulation, Preparation, and Storage
Purification
Reconstitution
Formulation
Shipping
Stability & Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: CA125/MUC16
MUC16, also known as the CA125 antigen, is a mucin protein that may be found in type I transmembrane or secreted forms that are used monitor the progress of epithelial ovarian cancer therapy (1, 2). Expression of isoforms, proteolytic cleavage, and heavy N- and O- linked glycosylation produce forms of human MUC16 that can vary from 1148 to 22152 amino acids (aa) in length and 200 - 5000 kDa in size (1, 2). The 22152 aa form contains ser/thr-rich N-terminal tandem repeats, 4 LRR (Leu-rich repeat) domains, 56 SEA (sea urchin sperm protein, enterokinase and agrin) domains, a transmembrane domain, and a 31 aa cytoplasmic domain that includes a tyrosine phosphorylation site (1-4). SEA domains are ~120 aa in length, contain conserved residues including potential O-glycosylation sites and a pair of cysteines, and are often found in transmembrane mucins (3). The protein produced by R&D Systems represents aa 13360-14347 of the full sequence and includes the last 6 SEA domains. It shares 68% aa identity with canine MUC16. MUC16 is over-expressed by tumor cells including ovarian and mesothelial cancers (5). The transmembrane form can adhere to mesothelin in the peritoneum, facilitating metastasis of ovarian cancer to the peritoneal cavity (5-7). MUC16 also binds galectin-1 on immune cells and enhances its expression on tumor cells (8). MUC16-expressing tumors adhere to NK cells, down-regulate CD16 and suppress NK response, which may promote immune evasion (9, 10). MUC16 is also cyclically expressed in the endometrium and may contribute to immune privilege during pregnancy (10). In the eye, MUC16 and other mucins protect the cornea and keep it hydrated. It is altered on the conjunctival epithelium of patients with non-Sjogren dry eye syndrome (11).
References
- Yin, B. W. T. K. O. Lloyd, 2001, J. Biol. Chem. 276:27371.
- Maeda, T. et al. (2004) J. Biol. Chem. 279:13174.
- Fendrick, J. L. et al. (1997) Tumour Biol. 18:278.
- Swissprot accession Q8WXI7.
- Kaneko, O. et al. (2009) J. Biol. Chem. 284:3739.
- Rump, A. et al. (2004) J. Biol. Chem. 279:9190.
- Gubbels, J. A. A. et al. (2006) Mol. Cancer 5:50.
- Seelenmeyer, C. et al. (2003) J. Cell Sci. 116:1305.
- Patankar, M. S. et al. (2005) Gynecol. Oncol. 99:704.
- Belisle, J. A. et al. (2007) Immunology 122:418.
- Blalock, T. D. et al. (2007) Invest. Ophthalmol. Vis. Sci. 48:4509.
Long Name
Alternate Names
Entrez Gene IDs
Gene Symbol
UniProt
Additional CA125/MUC16 Products
Product Documents for Human CA125/MUC16 Antibody
Product Specific Notices for Human CA125/MUC16 Antibody
For research use only